Could CRISPR help prevent the next global pandemic?

	HIV/AIDS
	The latest HIV/AIDS news from News Medical

CRISPR technology offers innovative solutions for pandemic preparedness, enhancing diagnostics, antiviral therapies, and vaccine development in public health.

			WHO study sheds light on global maternal mortality crisis Hemorrhage – severe heavy bleeding – and hypertensive disorders like preeclampsia are the leading causes of maternal deaths globally, according to a new study released today by the World Health Organization (WHO).

			Long-acting HIV injections show success in patients with struggles to take daily pills UCSF researchers are the first to demonstrate that the approach works for the patients who need it the most.

			The hidden risks of combining medications and dietary supplements When you take prescription or over-the-counter medications, do you also take a vitamin, mineral, or other dietary supplement? Have you considered whether there is any danger in mixing medications and dietary supplements?

	Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP).

	Gaps in HPV cancer screening and prevention identified for people living with HIV A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

	Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions.

	ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

	Dementia risk higher among adults with HIV in Malawi Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according to a new study by a team of US and Malawian researchers.

	Over 40,000 new gut microbes discovered in African populations More than 40,000 previously unknown gut microbes in African populations could completely change how medicines work for millions of people, according to scientists.

	Study reveals an integrated care model for improving outcomes among people who inject drugs Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2025